The comparison of effect of levetiracetam and sodium valproate on seizure attacks frequency of 8-30 year old patients with juvenile myoclonic epilepsy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013112715567N1

Enrollment

Registered

2014-02-15

Start date

2012-04-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized idiopathic epilepsy. Generalized idiopathic epilepsy and epileptic syndromes

Interventions

Intervention 1: Intervention group: Tab Levetiracetam500 mg orally twice a day for 28 weeks, from Sobhan Pharmaceutical Company. Intervention 2: Control group: Tab Sodium valproate 400 mg orally twice

Treatment - Drugs

Intervention group: Tab Levetiracetam500 mg orally twice a day for 28 weeks, from Sobhan Pharmaceutical Company

Control group: Tab Sodium valproate 400 mg orally twice a day for 28 weeks, from Sobhan Pharmaceutical Company

Eligibility

Sex/Gender

All

Age

8 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with juvenile myoclonic epilepsy; Age between 8 and 30; Absence of brain lesion in MRI; Normal neurologic physical examination. Exclusion criteria: Pregnancy; Secondary epilepsy; Levetiracetam, Lamotrigine or Sodium valproate receiving during last month; Severe organic disease; History of poor compliance.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Frequency of seizures. Timepoint: monthly. Method of measurement: according to history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Sadr

Jundishapur University of Medical Sciences

f.sadr61@gmail.com+98 61 1374 3012

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026